I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition.

Gao, Congying; Zhang, Lei; Xu, Yun; Ma, Xiangyu; Chen, Peilei; Chen, Zhe-Sheng; Wei, Liuya

Gao, Congying; Zhang, Lei; Xu, Yun; Ma, Xiangyu; Chen, Peilei; Chen, Zhe-Sheng; Wei, Liuya.

Afiliación

Gao C; School of Pharmacy, Weifang Medical University, Weifang, China.
Zhang L; School of Pharmacy, Weifang Medical University, Weifang, China.
Xu Y; School of Pharmacy, Weifang Medical University, Weifang, China.
Ma X; School of Pharmacy, Weifang Medical University, Weifang, China.
Chen P; School of Pharmacy, Weifang Medical University, Weifang, China.
Chen ZS; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, United States.
Wei L; School of Pharmacy, Weifang Medical University, Weifang, China.

Front Pharmacol ; 14: 1183052, 2023.

Article en En | MEDLINE | ID: mdl-37124196

Palabras clave

BCR-ABL-T315I mutation; HDAC inhibitor; acetylation of histones; chronic myeloid leukemia; imatinib resistance

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google